The NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir are coformulated in a single tablet. The regimen is pangenotypic and has a high barrier to resistance.
https://blog.naver.com/sjloveu2/221793077431
|
The combination tablet consists of 100 mg glecaprevir and 40 mg pibrentasvir. The daily dose consists of three tablets taken at the same time, administered with food. Glecaprevir and pibrentasvir can be used in patients with any degree of renal impairment, including those on dialysis, without the need for dose modifications. The regimen is contraindicated in patients with decompensated (Child-Pugh class B or C) cirrhosis because of a risk of worsening liver function or liver failure. In contrast, it is generally safe among patients with compensated (Child-Pugh class A) cirrhosis despite a two-fold increase in glecaprevir levels in such patients. Nevertheless, it is important to ensure that the liver disease is not more advanced. Dosing: Renal Impairment: Adult No dosage adjustment necessary. |
REF. UpToDate 2020.12.06
